FDA denies Amarin's appeal
September 12, 2014 at 13:32 PM EDT
The
Food and Drug Administration denied Amarin Corp.'s (Nasdaq: AMRN) appeal of
the agency's recession of the ANCHOR clinical trial Special Protocol
Assessment agreement sending the stock price down 40 cents to $1.41.